Skip to main content

Table 2 Treatment characteristics

From: Progression-free survival at 2 years is a reliable surrogate marker for the 5-year survival rate in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy

Treatment N = 159
Chemothrapy regimen-no. (%)   
   CBDCA + PTX 46 (29)
   CDDP + S-1 46 (29)
   CDDP + VNR 41 (26)
   MVP 14 (9)
   CBDCA + CPT-11 5 (3)
   CDDP + VP-16 4 (2)
   CDDP + VNR + DE-766 3 (2)
RT dose-Gy   
   Median 60
   Range 52-74
  1. Abbreviations: CBDCA carboplatin, PTX paclitaxel, CDDP cisplatin, VNR vinorelbine, MVP mitomycin, vindesine, and cisplatin, CPT-11 irinotecan, VP-16 etoposide, RT radiation therapy.